1. Home
  2. VSAT vs MIRM Comparison

VSAT vs MIRM Comparison

Compare VSAT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ViaSat Inc.

VSAT

ViaSat Inc.

HOLD

Current Price

$46.59

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$88.24

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSAT
MIRM
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.4B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
VSAT
MIRM
Price
$46.59
$88.24
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$46.20
$114.67
AVG Volume (30 Days)
1.4M
806.2K
Earning Date
02-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
50.88
74.59
EPS
N/A
N/A
Revenue
N/A
$19,138,000.00
Revenue This Year
$5.34
$26.22
Revenue Next Year
$3.59
$21.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.36
$36.88
52 Week High
$52.70
$109.28

Technical Indicators

Market Signals
Indicator
VSAT
MIRM
Relative Strength Index (RSI) 48.64 43.42
Support Level $41.76 $85.76
Resistance Level $50.53 $96.65
Average True Range (ATR) 3.20 3.59
MACD -0.18 -0.15
Stochastic Oscillator 21.04 29.33

Price Performance

Historical Comparison
VSAT
MIRM

About VSAT ViaSat Inc.

Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: